RNA-Guided Gene Regulation for Degenerative Disc Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for degenerative disc disease (DDD)-induced lower back pain (LBP) fail to prevent the progression of disc degeneration, and existing stem cell therapies struggle to maintain an exemplary phenotype in challenging disease environments, necessitating a method to inhibit inflammatory cytokine signaling and control cell phenotype without growth factors.
Innovation Solution
CRISPR-Cas systems are used to modulate gene expression in cells by introducing vectors with promoters linked to guide RNAs and regulatory elements, targeting specific DNA loci to inhibit inflammatory cytokine signaling and regulate gene expression, thereby slowing DDD progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell therapies are implanted into the intervertebral disc, then pain relief is achieved, but the stem cells struggle to maintain their phenotype in the challenging disease environment
Solution Approach 1:
The patent applies preliminary anti-action by pre-treating stem cells with anti-inflammatory agents and growth factors before implantation to prime them with anti-inflammatory and chondrogenic properties. This pre-conditioning enables the stem cells to resist the harmful inflammatory environment of the degenerative disc once implanted, maintaining their phenotype and functionality without requiring continuous external intervention in the challenging disease environment.
2Adaptability or versatility
If growth factors are used to control stem cell phenotype, then cell differentiation is achieved, but the complexity and cost of treatment increases
Solution Approach 1:
The patent extracts the essential function of growth factors by using a simplified single-factor system (TGF-β3) that specifically induces chondrogenic differentiation. This extraction approach replaces complex multi-factor growth factor regimens with a single, targeted factor that achieves the desired phenotypic control, thereby reducing treatment complexity and cost while maintaining effective cell differentiation.
Solution Approach 2:
The patent applies parameter changes by optimizing specific conditions (temperature, pH, concentration of TGF-β3) to achieve effective chondrogenic differentiation. By carefully controlling these parameters, the system achieves versatile phenotypic control without requiring complex treatment protocols, simplifying the overall system while maintaining adaptability.
3Object-generated harmful factors
If current treatments for DDD-induced LBP are applied, then symptoms are alleviated, but disc degeneration progression is not prevented
Solution Approach 1:
The patent converts the harmful inflammatory environment of DDD into a beneficial context by using the inflammatory cytokines (TNF-α, IL-1β) as indicators to target and modulate specific genes (TNFR1, IL1R1) that drive degeneration. By suppressing these specific receptors through CRISPR-Cas9 gene editing, the treatment addresses the root cause of degeneration rather than merely masking symptoms, thereby preventing progression while maintaining pain relief.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CRISPR-Cas systems effectively downregulate inflammatory cytokine receptors and enhance chondrogenic differentiation, reducing neuronal sensitization and promoting extracellular matrix production, providing a long-term solution for DDD-induced LBP.
Implementation Method 1
a promoter operably linked to one or more nucleotide sequences encoding a CRISPR-Cas system guide RNA (gRNA), wherein the gRNA hybridizes with a target sequence of a DNA locus in a cell
Implementation Method 2
CRISPR-Cas systems are used to modulate gene expression in cells by introducing vectors with promoters linked to guide RNAs and regulatory elements, targeting specific DNA loci to inhibit inflammatory cytokine signaling and regulate gene expression
Data Source
AI summary
Disclosed herein are compositions and methods for treatment and prevention of low back pain. The compositions include vectors comprising nucleotide sequences encoding one or more CRISPR-Cas system guide RNAs and a RNA-directed nuclease. The methods include modulating expression of one or more genes in a cell using the compositions, introducing a CRISPR-Cas system into a cell comprising one or more vectors comprising the compositions, including site-specific DNA cleavage in a cell, and treating a subject having lower back pain, and lower back pain caused by degenerative disc disease using the compositions disclosed herein.